Lates News

Each AI Express, China Galaxy released a research report on August 25 giving a recommendation rating for Dezai Medicine (688192.SH). The main reasons for the rating include: 1) Suvatinib has been approved by the FDA for market launch, and lorlatinib has shown significant clinical benefits; 2) Innovative pipeline progress smoothly, with impressive data on dual-target BTK and fourth-generation EGFRTKI. (Daily Economic News)